| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:IDO/Tubulin-IN-2
CAS:2409479-24-7
Package:100mg/RMB 19500;25mg/RMB 11700;50mg/RMB 15300
|
IDO/Tubulin-IN-2 manufacturers
- IDO/Tubulin-IN-2
-
- $0.00 / 1removed
-
2025-09-22
- CAS:2409479-24-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | IDO/Tubulin-IN-2 Basic information |
| Product Name: | IDO/Tubulin-IN-2 | | Synonyms: | IDO/Tubulin-IN-2;Benzoic acid, 3-[(4,9-dihydro-4,9-dioxo-1H-naphtho[2,3-d]triazol-1-yl)methyl]-, 2-[1-[[3-[[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxy]carbonyl]phenyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl ester | | CAS: | 2409479-24-7 | | MF: | C48H40N6O10 | | MW: | 860.87 | | EINECS: | | | Product Categories: | | | Mol File: | 2409479-24-7.mol |  |
| | IDO/Tubulin-IN-2 Chemical Properties |
| Boiling point | 1056.388±75.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.347±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 0.780±0.12(predicted) |
| | IDO/Tubulin-IN-2 Usage And Synthesis |
| Uses | IDO/Tubulin-IN-2 (HT2) is a potent TDO and tubulin inhibitor. IDO/Tubulin-IN-2 also shows potent activity against U87, HepG2, A549, HCT-116, and LO2 cancer cell lines, with IC50 values of 0.43, 0.036, 0.041, 0.095 and 1.04 μM, respectively. IDO/Tubulin-IN-2 remarkably promotes the antitumor activity[1]. | | in vivo | IDO/Tubulin-IN-2 (HT2) (30 mg/kg; IV; daily, for 21 days) significantly inhibits tumor growth[1].
IDO/Tubulin-IN-2 (30 mg/kg; IV; 29 days) has effective antitumor immunity ability to promote the tumor therapeutic efficacy[1]. | Animal Model: | ICR mice (mouse liver cancer xenograft models, established by subcutaneous inoculation of H22 cells)[1] | | Dosage: | 30 mg/kg | | Administration: | Intravenously injected via a tail vein; daily, for 21 days | | Result: | Significantly inhibited tumor growth. |
| Animal Model: | Male A549 tumor xenograft BALB/c nude mice (5 weeks, 18-22 g)[1] | | Dosage: | 30 mg/kg | | Administration: | IV, daily, for 29 days | | Result: | Had effective antitumor immunity ability to promote the tumor therapeutic efficacy. |
| | References | [1] Hua S, Chen F, Gou S. Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase. Eur J Med Chem. 2020;187:111949. DOI:10.1016/j.ejmech.2019.111949 |
| | IDO/Tubulin-IN-2 Preparation Products And Raw materials |
|